iBio, Inc.

NASDAQ:IBIO

Biotechnology

Healthcare
$0.85 +0.00%

+$0.00 today

Market cap
$59.75M
Beta
1.29
P/E (TTM)
-3.6
EPS (TTM)
-$0.32
52W Low $0.78High $3.82

Volume 0.84M

Average 0.81M

IBIO Debt Repayment

Cash used to repay borrowings during the period.

iBio, Inc.NASDAQ: IBIO

Debt Repayment · Q4 FY2026 · quarter ended Jun 2026

Debt repayment growth accelerates

Q4 FY2026 debt repayment of $5.86M (cash outflow) rose 3102.2% year over year, ahead of the +854.5% change in trailing-twelve-month debt repayment. Over 3 fiscal years it compounded at -10.1% a year.

Context

  • Debt repayment amounted to 6634.0% of revenue in FY2026, up 6441.3 pp from a year earlier.
  • Debt repayment grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +3102.2% holds above the trailing-twelve-month pace of +854.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$5.86M— QoQ
Last fiscal yearJun 2026
-$6.63M+760.4% YoY
LTMJun 2026
-$6.63M+854.5% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3102.2%——
1 year+760.4%——
3-year CAGR-10.1%——
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2026
(6.63M) USD
Year-over-year change
-760.4%

Debt Repayment vs competitors

How IBIO compares with its peers on the latest reported figures

  • IBIO's LTM Jun 2026 debt repayment of $6.63M is the largest of the 4 companies compared; the peer median is $0.
  • Debt repayment amounts to 6634.0% of revenue for IBIO, versus a peer median of 0.0%.
IBIO Competitors Peer median
Debt Repayment for IBIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IBIOiBio, Inc.LTM Jun 2026$6.63M +854.5%-10.1%6634.0%
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$0 ———
RLYBRallybio CorporationLTM Mar 2026$0 ——0.0%
BOLDBoundless Bio, Inc.LTM Mar 2026$0 ———
Peer median (excluding IBIO) $0——0.0%

Competitors are the stored peer set for IBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
FY2026
Jun 2026
Net Income(29.51M)(65.01M)(24.91M)(18.38M)(33.04M)
Depreciation & Amortization3.79M1.38M1.25M291K88K
Deferred Income Tax00000
Stock-Based Compensation4.38M4.39M2.04M1.53M1.37M
Change in Working Capital3.24M5.87M(3.17M)479K2.52M
Accounts Receivables4.21M6.1M00(65K)
Inventory(3.87M)(1.02M)000
Accounts Payables1.24M(625K)(1.49M)1.83M2.22M
Other Working Capital1.66M1.41M(1.68M)(1.35M)364K
Other Non-Cash Items(15.32M)22.93M6.23M773K5.84M
Operating Cash Flow(37.8M)(30.44M)(18.55M)(15.3M)(23.22M)
Capital Expenditures(7.33M)(5.74M)(210K)(16K)(578K)
Acquisitions (Net)0(692K)000
Purchases of Investments(7.12M)000(42.3M)
Sales of Investments13.62M10.84M000
Other Investing Activities(4.3M)2.6M1.12M758K10.88M
Investing Cash Flow(5.13M)7.01M906K742K(32M)
Debt Repayment(5.83M)(9.13M)(1.14M)(771K)(6.63M)
Common Stock Issued77K11.49M25.52M9.7M109.58M
Common Stock Repurchased0(39K)(7K)00
Dividends Paid00000
Other Financing Activities(50K)(22K)197K0105K
Financing Cash Flow(5.8M)2.3M24.49M8.93M103.05M
Effect of Forex Changes(6M)33K00(18K)
Net Change in Cash(54.73M)(21.09M)6.85M(5.63M)47.83M
Free Cash Flow(45.13M)(36.17M)(18.76M)(15.32M)(23.8M)

iBio, Inc.

NASDAQ:IBIO

Intrinsic Alpha fair value

Locked

Current Price

$0.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.